EpiCast Report: Hemophilia – Epidemiology Forecast to 2026

2017-07-01
Price :
Published : Jul-2017
No. of Pages : 39

EpiCast Report: Hemophilia – Epidemiology Forecast to 2026

Summary

Hemophilia is an X-linked hereditary bleeding disorder, characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (FVIII) in hemophilia A or factor IX (FIX) in hemophilia B (Bolton-Maggs and Pasi, 2003). Because of the deficiency of coagulation factor, hemophilia patients have a tendency for bleeding in joints, muscles, soft tissues, and within mucous membranes, which can be either spontaneous or due to internal or external trauma, depending on the severity of the disease (CDC, 2017b; Mayo Clinic, 2014).

In the 7MM, epidemiologists forecast an increase in the diagnosed prevalent cases of hemophilia A and hemophilia B, from 51,627 diagnosed prevalent cases in 2016 to 52,566 diagnosed prevalent cases in 2026, with an Annual Growth Rate (AGR) of 0.18% during the forecast period. The US will have the highest number of diagnosed prevalent cases of hemophilia A and hemophilia B among the 7MM throughout the forecast period, while Spain will have the lowest.

Among the 7MM in 2016, the UK had the highest age-standardized diagnosed prevalence of hemophilia A in men with 20.36 cases per 100,000 population and in women with 0.60 cases per 100,000 population. The age-standardized diagnosed prevalence of hemophilia A in Germany was lowest in men with 9.61 cases per 100,000 population and in women with 0.28 cases per 100,000 population.

The report “EpiCast Report: Hemophilia – Epidemiology Forecast to 2026” provides an overview of the comorbidities and the global and historical trends for hemophilia in seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of hemophilia segmented by type (hemophilia A and hemophilia B), sex, and age (for all ages) in these markets. The diagnosed prevalent cases of hemophilia A and hemophilia B by severity and with inhibitors were also provided in the report.

Scope

– The Hemophilia EpiCast Report provides an overview of the risk factors and global trends of hemophilia in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of diagnosed prevalent cases of hemophilia segmented by type (hemophilia A and hemophilia B), sex, and age (for all ages) in these seven markets.
– The hemophilia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Hemophilia EpiCast report will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global hemophilia market.
– Quantify patient populations in the global hemophilia market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for hemophilia therapeutics in each of the markets covered.
– Identify the percentage of hemophilia prevalent cases by type.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Parkinson’s Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects

Parkinson's Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects Summary Parkinson's disease (PD), a progressive neurological disorder that affects movement control, is associated with considerable quality of life impairments and burden of care, particularly in the advanced disease stages. Cognitive and behavioral complications of PD are common. PD-associated dementia and PD-associated psychosis are both highly prevalent and associated with a large disease burden. There is a pressing unmet need within PD, PD-associated dementia, and PD-associated psychosis for more effective disease-modifying pharmacotherapies. Although current therapies can provide patients with symptomatic relie......
$6995

Obesity: Gut Hormone Receptors Retain Commercial Prominence

Obesity: Gut Hormone Receptors Retain Commercial Prominence Summary Obesity is a chronic and potentially fatal disease. The most prevalent metabolic disorder affecting people today, obesity requires multidisciplinary continuing treatment. Despite the market's clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, which is in line with its multifactorial etiology. The primary concern within the market is the need for medications that adequately address the unmet clinical needs in the overweight and obese population, namely efficacious and safe therapies. This report assesses first-in-class innovation across the obesity pipeline. Scope - The obesity pipeline is robust and contains a high leve......
$6995

Hepatitis B: Competitive Landscape to 2027

Hepatitis B: Competitive Landscape to 2027 Summary Hepatitis B is a viral infection of the liver that can become chronic in young children, especially newborns to mothers with HBV infections, and people with compromised immune systems. Chronic hepatitis B is defined as measurable Hepatitis surface antigen (HBsAg) levels for more than six months after an acute infection. Despite the existence of prophylactic vaccines, hepatitis B remains a global public health threat, with approximately 257 million people worldwide living with chronic HBV infections. Chronic hepatitis B cannot be cured and patients have elevated risks of developing liver cirrhosis and hepatocellular carcinoma (HCC). This report provides an assessment of the pipeline, clinical, and commercial landscape of Hepatitis B. Ov......
$3495

Pediatric Vaccines: Epidemiology Forecast to 2028

Pediatric Vaccines: Epidemiology Forecast to 2028 Summary The administration of a vaccine, referred to as vaccination, elicits an immune response that prevents an individual from developing a specific disease when exposed to the corresponding infectious agent in the future. A successful vaccination results in immunization, where the individual is deemed immune to the disease. Routine immunization programs aim to protect children at an early age, when they are the most vulnerable to disease. Prior to the discovery of vaccines, several infectious diseases claimed the lives of millions of children each year. GlobalData epidemiologists utilized comprehensive, country-specific vaccination rate data from nationally representative public health surveillance systems and databases to arrive at ......
$3995

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Global Clinical Trials Review, H1, 2019

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Global Clinical Trials Review, H1, 2019" provides an overview of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) clinical trials scenario. This report provides top line data relating to the clinical trials on Congenital Adrenal Hyperplasia (Adrenogenital Syndrome). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based ......
$2500

Chronic Urticaria Or Hives Global Clinical Trials Review, H1, 2019

Chronic Urticaria Or Hives Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Chronic Urticaria Or Hives Global Clinical Trials Review, H1, 2019" provides an overview of Chronic Urticaria Or Hives clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Urticaria Or Hives. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary databas......
$2500

Cryptosporidiosis Global Clinical Trials Review, H1, 2019

Cryptosporidiosis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Cryptosporidiosis Global Clinical Trials Review, H1, 2019" provides an overview of Cryptosporidiosis clinical trials scenario. This report provides top line data relating to the clinical trials on Cryptosporidiosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials da......
$2500

Colitis Global Clinical Trials Review, H1, 2019

Colitis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Colitis Global Clinical Trials Review, H1, 2019" provides an overview of Colitis clinical trials scenario. This report provides top line data relating to the clinical trials on Colitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated fro......
$2500

Degenerative Scoliosis Global Clinical Trials Review, H1, 2019

Degenerative Scoliosis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Degenerative Scoliosis Global Clinical Trials Review, H1, 2019" provides an overview of Degenerative Scoliosis clinical trials scenario. This report provides top line data relating to the clinical trials on Degenerative Scoliosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrac......
$2500

Conjunctivitis Global Clinical Trials Review, H1, 2019

Conjunctivitis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Conjunctivitis Global Clinical Trials Review, H1, 2019" provides an overview of Conjunctivitis clinical trials scenario. This report provides top line data relating to the clinical trials on Conjunctivitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clin......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy